In addition, ipilimumab treatment of melanoma with baseline high levels of circulating Tregs was associated with OS, possibly as a target for ipilimumab antibody ADCC due to its high CTLA-4 expression; whereas decreased or stabilized circulating Tregs at 12 weeks since ipilimumab initial administration was significantly associated with better DCR and OS [98]. Here, CTLA4 is linked to melanoma.